For the supportive treatment of urinary tract infections. Prevents the formation of kidney stones.

Formulations are indicated for the treatment of mild to moderately severe infections caused by susceptible organisms.

Is indicated for the treatment of infections caused by susceptible strains of organisms in the following infections :- Upper Respiratory Tract Infections: Pneumococcal infections – Pneumonia, bronchitis, cellulitis, otitis media. Heamophilus influenzae infections – Otitis media, laryngotracheobronchitis, meningtitis (in children). Urinary tract infections:  E. coli infections – pneumonia, urinary tract infections, meningtitis (in children). Gastro-intestinal infections: Shigella infections – Bacillary dysentery. Salmonella infections – Enteritis. Other: Neisseria meningitides – Meningitis (in children). Acute uncomplicated cystitis caused by E. Coli and Klebsiella pneumonia. Note:  Bacteriological tests determine causative organisms and sensitivities are recommended. AUSTELL-CEFOTAXIME is indicated peri-operatively to reduce the incidence of post-operative infections in patients undergoing surgical procedures classified as potentially contaminated.

Is indicated for the following infections: Bacterial septicemia, meningitis, intra-abdominal infections, skin infections, bone & joint infections, renal & urinary tract infection, respiratory tract infection, ear, nose and throat infections, uncomplicated Gonorrhoea.

Tablets are indicated for the treatment of the following infections, when caused by susceptible organisms: Lower Respiratory Tract Infections caused by: Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniea, Proteus mirabilis, Pseudomonas aeruginosa. Urinary tract infections caused by: Citrobacter diversus, Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Providencia rettgeri, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus epidermidis, Streptococcus faecalis. Skin and soft tissue infections caused by: Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella pnuemoniae, Morgenella morganii, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes. Gastro-intestinal tract infections: Infective diarrhoea caused by Campylobacter jejuni, Eschericia coli, Shigella flexneri and Shigella sonnei. Bone infections: Osteomyelitis due to susceptible Gram-negative organisms. Gonorrhoea.

Indicated for the treatment of infections caused by amoxicillin resistant organisms producing beta-lactamases sensitive to clavulanic acid: Upper respiratory tract infections, such as sinusitis, recurrent otitis media, and tonsillitis. Lower respiratory tract infections, such as bronchitis and bronchopneumonia. Genito-urinary tract infections, such as cystitis, urethritis, pyelonephritis. Skin and soft tissue infections. AUSTELL CO- AMOXICLAV will also be effective in the treatment of infections caused by amoxicillin sensitive organisms at the appropriate amoxicillin dosage since in this situation the clavulanic acid component does not contribute to the therapeutic effect.

Is indicated for the treatment of the following conditions in adults: Cryptococcal meningitis in mentally alert patients without localising neurological signs and as a follow up therapy after Amphotericin B therapy. Maintenance therapy to prevent relapse of cryptococcal disease in patients with acquired immunodeficiency syndrome (AIDS). Systemic candidiasis. Oropharyngeal and oesophageal candidiasis. Prophylaxis of fungal infections in patients receiving cytotoxic chemotherapy and/or radiation therapy. Vaginal candidiasis – Acute or recurrent infections and as prophylaxis to reduce the incidence of recurrent infections. Candidial balanitis. Dermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea unguium (onychomycosis) and dermal candida infections.